AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12944032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine ER
Number of subjects: 192
Study 12944032 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 192
Study 12944032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine ER and Amlodipine
Number of subjects: 192
Study 11151420 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa
Number of subjects: 60
Study 11151420 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine
Number of subjects: 60
Study 11151420 — intervention group
Group type: EXPERIMENTAL
Intervention: selegiline
Number of subjects: 60
Study 11151420 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 60
Study 9088588 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily for 14 days)
Number of subjects: 12
Study 9088588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8491252 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg
Number of subjects: 8
Study 8491252 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8
Study 8491252 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8
Study 8491252 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 150 mg
Number of subjects: 8
Study 3438883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar saline
Number of subjects: 20
Study 3438883 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 20
Study 29362244 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) plus standard oncologic care
Number of subjects: 480
Study 29362244 — intervention group
Group type: COMPARATOR
Intervention: Standard oncologic care
Number of subjects: 480
Study 26322917 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid (O3FA) oral supplement (2,400 mg/day) for 45 days
Number of subjects: 256
Study 26322917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil, 8 capsules)
Number of subjects: 256
Study 25404192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883
Study 25404192 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 3883
Study 23695483 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (5 mg/d titrated to 20 mg/d over 6 weeks)
Number of subjects: 127
Study 23695483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 23695483 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 127
Study 20584124 — intervention group
Group type: EXPERIMENTAL
Intervention: PSD502
Number of subjects: 256
Study 20584124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 18261166 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid) 1800 mg daily from day 4 to day 14
Number of subjects: 101
Study 18261166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 101
Study 16173532 — intervention group
Group type: EXPERIMENTAL
Intervention: External Qi therapy (EQT)
Number of subjects: 30
Study 16173532 — intervention group
Group type: COMPARATOR
Intervention: Placebo control therapy
Number of subjects: 30
Study 12921918 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 5 mg/day (under 5 years) and 10 mg/day (over 5 years)
Number of subjects: 28
Study 12921918 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate 1 mg/kg/day
Number of subjects: 28
Study 10937097 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser treatment alone
Number of subjects: 10
Study 10937097 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser treatment followed by erbium:YAG laser treatment
Number of subjects: 10
Study 10937097 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser treatment alone
Number of subjects: 10
Study 10937097 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser treatment followed by carbon dioxide laser treatment
Number of subjects: 10
Study 10937097 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin subjected to laser treatment
Number of subjects: 10
Study 8669575 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml bupivacaine 0.5% + 25 mg (0.5 ml) ketamine + 1 in 200,000 adrenaline
Number of subjects: 30
Study 8669575 — intervention group
Group type: COMPARATOR
Intervention: 20 ml bupivacaine 0.5% + 0.5 ml 0.9% saline + 1 in 200,000 adrenaline
Number of subjects: 30
Study 8669575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 1705348 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based case management services
Number of subjects: 0
Study 1705348 — intervention group
Group type: COMPARATOR
Intervention: Traditional discharge and follow-up services of a NICU
Number of subjects: 0
Study 1705348 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition model (additional 7% referred)
Number of subjects: 0
Study 6721765 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-strength povidone-iodine (Betadine) solution
Number of subjects: 30
Study 6721765 — intervention group
Group type: COMPARATOR
Intervention: Control (second eye)
Number of subjects: 30
Study 30859938 — intervention group
Group type: COMPARATOR
Intervention: BUP/SAM 2mg/2mg
Number of subjects: 38
Study 30859938 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP/SAM 8mg/8mg
Number of subjects: 38
Study 30859938 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP/SAM 16mg/16mg
Number of subjects: 38
Study 30859938 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP alone 8mg
Number of subjects: 38
Study 30859938 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP alone 16mg
Number of subjects: 38
Study 30006669 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk fatigue
Number of subjects: 16
Study 30006669 — intervention group
Group type: COMPARATOR
Intervention: Control (rest period)
Number of subjects: 16
Study 27257288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 1665
Study 27257288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 1665
Study 27257288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (both dosages)
Number of subjects: 1665
Study 27257288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1665
Study 24305572 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple group sessions for IDUs and family members
Number of subjects: 166
Study 22976741 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) - aerobic training program (3-4 sessions/week, 50 min/session, at 70% maximum heart rate)
Number of subjects: 43
Study 22976741 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) - aerobic training program
Number of subjects: 43
Study 22976741 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 43
Study 19250071 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT) for 8 weeks
Number of subjects: 41
Study 17309381 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet cupping (treated group, N = 23)
Number of subjects: 47
Study 17309381 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group, N = 24)
Number of subjects: 47
Study 15201136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 114
Study 15201136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint
Number of subjects: 114
Study 15201136 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 114
Study 11531671 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 U unfractionated heparin subcutaneously after surgery
Number of subjects: 23
Study 11531671 — intervention group
Group type: EXPERIMENTAL
Intervention: 7500 U unfractionated heparin subcutaneously after surgery
Number of subjects: 23
Study 11531671 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 U unfractionated heparin subcutaneously after surgery
Number of subjects: 23
Study 9846590 — intervention group
Group type: EXPERIMENTAL
Intervention: autoclaved retrograded high-amylose corn starch (HACS)
Number of subjects: 7
Study 9846590 — intervention group
Group type: COMPARATOR
Intervention: drum-dried ordinary corn starch
Number of subjects: 7
Study 7985709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amphotericin B (0.1 mg/kg per day)
Number of subjects: 35
Study 7985709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2728961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 131
Study 2728961 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 131
Study 2728961 — intervention group
Group type: COMPARATOR
Intervention: Behavioral training alone
Number of subjects: 131
Study 30689597 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric Adjustable Height Desks (EAHD)
Number of subjects: 0
Study 29208686 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration (20 μg/kg sc 3×/week) for 26 weeks
Number of subjects: 72
Study 29208686 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 72
Study 25524023 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate/cholecalciferol
Number of subjects: 30
Study 25524023 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone
Number of subjects: 30
Study 24693681 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant nutrients supplement (AO) for 5 days prior to surgery
Number of subjects: 23
Study 24693681 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT) with no supplement
Number of subjects: 23
Study 20801521 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 1052
Study 20801521 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score (15-point GA risk score)
Number of subjects: 1052
Study 20801521 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score (5-factor risk score)
Number of subjects: 1052
Study 19546522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporine (CsA) 2.5 mg/kg body weight
Number of subjects: 54
Study 19546522 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g daily
Number of subjects: 54
Study 19546522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporine (CsA)
Number of subjects: 54
Study 19546522 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 54
Study 19546522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporine (CsA) and Mycophenolate mofetil (MMF)
Number of subjects: 54
Study 16682258 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric formula
Number of subjects: 37
Study 16682258 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 37
Study 15474755 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/MPA (conjugated estrogen 0.625 mg + medroxyprogesterone acetate 5 mg)
Number of subjects: 92
Study 15474755 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (17‐beta‐estradiol 2 mg + norethisterone acetate 1 mg)
Number of subjects: 92
Study 11374601 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 37 degrees C
Number of subjects: 33
Study 11374601 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 34 degrees C
Number of subjects: 33
Study 11374601 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 31 degrees C
Number of subjects: 33
Study 9247524 — intervention group
Group type: EXPERIMENTAL
Intervention: DM (DDDR with mode switching)
Number of subjects: 48
Study 9247524 — intervention group
Group type: COMPARATOR
Intervention: VR (VVIR)
Number of subjects: 48
Study 9247524 — intervention group
Group type: COMPARATOR
Intervention: DR (DDDR with conventional upper rate behavior)
Number of subjects: 48
Study 8295016 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water immersion (WI)
Number of subjects: 93
Study 8295016 — intervention group
Group type: COMPARATOR
Intervention: No warm water immersion (no-WI)
Number of subjects: 93
Study 2436359 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol therapy
Number of subjects: 62
Study 2436359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of glycerol and dextran
Number of subjects: 62
Study 2436359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 28826262 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical propolis ointment (5%; twice daily)
Number of subjects: 0
Study 28826262 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies alone
Number of subjects: 0
Study 27583920 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia (n = 23)
Number of subjects: 45
Study 27583920 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia (n = 22)
Number of subjects: 45
Study 24841843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine exposure (40 mg, IV)
Number of subjects: 28
Study 24841843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22279132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 55
Study 20332738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg . kg‐1. min‐1)
Number of subjects: 80
Study 20332738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17418537 — intervention group
Group type: EXPERIMENTAL
Intervention: 5HT2 receptor antagonists (trazodone or nefazodone)
Number of subjects: 988
Study 17418537 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 988
Study 15725138 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tube removal at 24 hours (Group A)
Number of subjects: 83
Study 11888973 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube for intermittent subglottic secretions drainage
Number of subjects: 150
Study 11888973 — intervention group
Group type: COMPARATOR
Intervention: Standard endotracheal tube
Number of subjects: 150
Study 10443663 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide with vitamin K2 (group B)
Number of subjects: 110
Study 10443663 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide with 1,25‐(OH)2D3 (group C)
Number of subjects: 110
Study 10443663 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide with vitamin K2 and 1,25‐(OH)2D3 (group D)
Number of subjects: 110
Study 10443663 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide only (group A)
Number of subjects: 110
Study 8666860 — intervention group
Group type: COMPARATOR
Intervention: 300 mg aerosolized pentamidine (AP) once-monthly
Number of subjects: 205
Study 8666860 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aerosolized pentamidine (AP) twice-monthly
Number of subjects: 205
Study 8666860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 205
Study 2134327 — intervention group
Group type: EXPERIMENTAL
Intervention: IdB 1027 (600 mg b.i.d.) for 10 days
Number of subjects: 8
Study 7356895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous disopyramide
Number of subjects: 8
Study 7356895 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disopyramide
Number of subjects: 8
Study 31325212 — intervention group
Group type: EXPERIMENTAL
Intervention: JR-131
Number of subjects: 334
Study 31325212 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 334
Study 30892810 — intervention group
Group type: EXPERIMENTAL
Intervention: 2RDA (1.6 g kg‐1 day‐1)
Number of subjects: 31
Study 30892810 — intervention group
Group type: COMPARATOR
Intervention: RDA (0.8 g kg‐1 day‐1)
Number of subjects: 31
Study 27329344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance intervention
Number of subjects: 0
Study 27329344 — intervention group
Group type: COMPARATOR
Intervention: Control (no incentives)
Number of subjects: 0
Study 25794201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided greater occipital nerve block (GONB) with bupivacaine 0.5% (1.5 mL)
Number of subjects: 32
Study 25794201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 0.9% 1.5 mL)
Number of subjects: 32
Study 24437202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonotherapy and klimadynon (herbal medicine with estrogen-like action)
Number of subjects: 0
Study 21719111 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbon dioxide exposure
Number of subjects: 8
Study 21719111 — intervention group
Group type: COMPARATOR
Intervention: Placebo room air
Number of subjects: 8
Study 21719111 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive clonazepam
Number of subjects: 8
Study 19301038 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) therapy
Number of subjects: 60
Study 19301038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer therapy
Number of subjects: 60
Study 17525363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 17525363 — intervention group
Group type: COMPARATOR
Intervention: UFH+eptifibatide
Number of subjects: 0
Study 16182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock group (n=72)
Number of subjects: 182
Study 16182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis group (n=56)
Number of subjects: 182
Study 16182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis group (n=54)
Number of subjects: 182
Study 16182977 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 182
Study 16182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis
Number of subjects: 182
Study 12888182 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B serum concentrations in patients with major depression
Number of subjects: 25
Study 12888182 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 12888182 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B serum concentrations
Number of subjects: 25
Study 10570386 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose narrow-band UVB phototherapy with calcipotriol ointment (50 microg/g) applied twice daily
Number of subjects: 53
Study 10570386 — intervention group
Group type: COMPARATOR
Intervention: Low-dose narrow-band UVB phototherapy without calcipotriol ointment
Number of subjects: 53
Study 8673999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (AI) with tumor-infiltrating lymphocytes (TIL) and recombinant interleukin-2 (rIL-2)
Number of subjects: 113
Study 8673999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (AI)
Number of subjects: 113
Study 8673999 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy
Number of subjects: 113
Study 1651060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostam (20 mg Sb/kg/day intramuscularly for 20 days)
Number of subjects: 61
Study 1651060 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol ribonucleoside (1,500 mg QID) plus probenecid (500 mg QID) for 28 days
Number of subjects: 61
Study 1651060 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 61
Study 7044709 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment group
Number of subjects: 25
Study 7044709 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 25
Study 30938155 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible-light-sensitive azo-dye and mesogenic acrylate doped to host liquid crystals, stabilized by unpolarized UV-light irradiation.
Number of subjects: 0
Study 30938155 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive mesogens (RMs) in an LC host photopolymerized into thin interfacial layers.
Number of subjects: 0
Study 27630010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast eating (within 5 minutes)
Number of subjects: 26
Study 27630010 — intervention group
Group type: COMPARATOR
Intervention: Slow eating (within 30 minutes)
Number of subjects: 26
Study 25669614 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Polamidon® 5 mg tablets (test)
Number of subjects: 33
Study 25669614 — intervention group
Group type: COMPARATOR
Intervention: L-Polamidon® solution for substitution (reference)
Number of subjects: 33
Study 25669614 — intervention group
Group type: EXPERIMENTAL
Intervention: Test/Reference (T/R) adjusted geometric mean ratios
Number of subjects: 33
Study 25669614 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Events
Number of subjects: 33
Study 24393008 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-containing bicarbonate dialysate
Number of subjects: 0
Study 24393008 — intervention group
Group type: COMPARATOR
Intervention: Acetate-free dialysate
Number of subjects: 0
Study 21898754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-diabetes drugs + basal insulin
Number of subjects: 129
Study 21898754 — intervention group
Group type: COMPARATOR
Intervention: Oral anti-diabetes drugs alone
Number of subjects: 129
Study 18977068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (P) therapy
Number of subjects: 32
Study 18977068 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 32
Study 17342426 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of embryo transfer > 10 < 15 mm (group A)
Number of subjects: 104
Study 17342426 — intervention group
Group type: COMPARATOR
Intervention: Depth of embryo transfer <= 10 mm (group B)
Number of subjects: 104
Study 16680621 — intervention group
Group type: EXPERIMENTAL
Intervention: First randomization strategy using 35-word lists based on recognition performance at each S/B ratio
Number of subjects: 120
Study 16680621 — intervention group
Group type: EXPERIMENTAL
Intervention: Second randomization strategy using 35-word lists based on recognition performance only
Number of subjects: 120
Study 11965204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use (cigarette, cigar, or pipe)
Number of subjects: 0
Study 11965204 — intervention group
Group type: EXPERIMENTAL
Intervention: Former tobacco use
Number of subjects: 0
Study 9862541 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair basketball players
Number of subjects: 23